Estradiol and Tamoxifen Induce Cell Migration through GPR30 and Activation of Focal Adhesion Kinase (FAK) in Endometrial Cancers with Low or without Nuclear Estrogen Receptor α (ERα)

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Tsai, Chia Lung ^a,b   Wu, Hsien Ming ^a   Lin, Chiao Yun ^a   Lin, Yi Jun ^a   Chao, Angel ^a   Wang, Tzu Hao ^a,b   Hsueh, Swei ^a   Lai, Chyong Huey ^a   Wang, Hsin Shih ^a,c  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FOCAL ADHESION KINASE; G PROTEIN COUPLED RECEPTOR 30; HYDROXYTAMOXIFEN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; TYROSINE;

ARTICLE; CANCER GROWTH; CELL MIGRATION; CELL NUCLEUS; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE EXPRESSION; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TAMOXIFEN; TYROSINE;

EID: 84883645377     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072999     Document Type: Article

References (51)

1. Kovacs EJ, Messingham KA, Gregory MS, (2002) Estrogen regulation of immune responses after injury. Mol Cell Endocrinol 193: 129-135.
2. Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, et al. (2008) Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol 70: 165-190.
3. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, et al. (2004) Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A 101: 1566-1571.
4. Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M, (2000) Multiple actions of steroid hormones - a focus on rapid, nongenomic effects. Pharmacol Rev 52: 513-556.
5. Filardo EJ, Thomas P, (2005) GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab 16: 362-367.
6. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr, (2000) Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 14: 1649-1660.
7. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER, (2005) A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307: 1625-1630.
8. Thomas P, Pang Y, Filardo EJ, Dong J, (2005) Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146: 624-632.
9. Isensee J, Meoli L, Zazzu V, Nabzdyk C, Witt H, et al. (2009) Expression pattern of G protein-coupled receptor 30 in LacZ reporter mice. Endocrinology 150: 1722-1730.
10. Olde B, Leeb-Lundberg LM, (2009) GPR30/GPER1: searching for a role in estrogen physiology. Trends Endocrinol Metab 20: 409-416.
11. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, et al. (2004) The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem 279: 27008-27016.
12. Prossnitz ER, Maggiolini M, (2009) Mechanisms of estrogen signaling and gene expression via GPR30. Mol Cell Endocrinol 308: 32-38.
13. Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, et al. (2006) 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30. Mol Pharmacol 70: 1414-1423.
14. Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, et al. (2007) GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol 196: 386 e381-389; discussion 386 e389-311.
15. Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, et al. (2009) GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol 114: 465-471.
16. Ignatov T, Eggemann H, Semczuk A, Smith B, Bischoff J, et al. (2010) Role of GPR30 in endometrial pathology after tamoxifen for breast cancer. Am J Obstet Gynecol 203: 595 e599-516.
17. Mitra SK, Hanson DA, Schlaepfer DD, (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6: 56-68.
18. Robles E, Gomez TM, (2006) Focal adhesion kinase signaling at sites of integrin-mediated adhesion controls axon pathfinding. Nat Neurosci 9: 1274-1283.
19. van Nimwegen MJ, van de Water B, (2007) Focal adhesion kinase: a potential target in cancer therapy. Biochem Pharmacol 73: 597-609.
20. Miyazaki T, Kato H, Nakajima M, Sohda M, Fukai Y, et al. (2003) FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer 89: 140-145.
21. Creasman WT, (2002) Estrogen and cancer. Gynecol Oncol 86: 1-9.
22. Lepine J, Audet-Walsh E, Gregoire J, Tetu B, Plante M, et al. (2010) Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways. J Clin Endocrinol Metab 95: 2689-2698.
23. Flamini MI, Sanchez AM, Genazzani AR, Simoncini T, (2011) Estrogen regulates endometrial cell cytoskeletal remodeling and motility via focal adhesion kinase. Fertil Steril 95: 722-726.
24. Way DL, Grosso DS, Davis JR, Surwit EA, Christian CD, (1983) Characterization of a new human endometrial carcinoma (RL95-2) established in tissue culture. In Vitro 19: 147-158.
25. Nishida M, Kasahara K, Kaneko M, Iwasaki H, Hayashi K, (1985) [Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors]. Nippon Sanka Fujinka Gakkai Zasshi 37: 1103-1111.
26. Wang TH, Chao AS, Chen JK, Chao A, Chang YL, et al. (2009) Network analyses of differentially expressed proteins in amniotic fluid supernatant associated with abnormal human karyotypes. Fertil Steril 92: 96-107.
27. Wang TH, Chao A, Tsai CL, Chang CL, Chen SH, et al. (2010) Stress-induced phosphoprotein 1 as a secreted biomarker for human ovarian cancer promotes cancer cell proliferation. Mol Cell Proteomics 9: 1873-1884.
28. Chao A, Lin CY, Lee YS, Tsai CL, Wei PC, et al. (2012) Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2. Oncogene 31: 764-775.
29. Tsai CL, Tsai CN, Lin CY, Chen HW, Lee YS, et al. (2012) Secreted stress-induced phosphoprotein 1 activates the ALK2-SMAD signaling pathways and promotes cell proliferation of ovarian cancer cells. Cell Rep 2: 283-293.
30. Chao A, Wang TH, Lee YS, Hsueh S, Chao AS, et al. (2006) Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression. Int J Cancer 119: 91-98.
31. Albanito L, Sisci D, Aquila S, Brunelli E, Vivacqua A, et al. (2008) Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology 149: 3799-3808.
32. Chao A, Tsai CL, Wei PC, Hsueh S, Chao AS, et al. (2010) Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma. Cancer Lett 291: 99-107.
33. Siesser PM, Hanks SK, (2006) The signaling and biological implications of FAK overexpression in cancer. Clin Cancer Res 12: 3233-3237.
34. Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, et al. (2008) A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. J Med Chem 51: 7405-7416.
35. Thamilselvan V, Craig DH, Basson MD, (2007) FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway. FASEB J 21: 1730-1741.
36. Filardo EJ, (2002) Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol 80: 231-238.
37. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, et al. (2009) Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J 28: 523-532.
38. Pirone DM, Liu WF, Ruiz SA, Gao L, Raghavan S, et al. (2006) An inhibitory role for FAK in regulating proliferation: a link between limited adhesion and RhoA-ROCK signaling. J Cell Biol 174: 277-288.
39. Otto C, Rohde-Schulz B, Schwarz G, Fuchs I, Klewer M, et al. (2008) G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinology 149: 4846-4856.
40. Madak-Erdogan Z, Kieser KJ, Kim SH, Komm B, Katzenellenbogen JA, et al. (2008) Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors. Mol Endocrinol 22: 2116-2127.
41. Pedram A, Razandi M, Levin ER, (2006) Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol 20: 1996-2009.
42. Ahola TM, Manninen T, Alkio N, Ylikomi T, (2002) G protein-coupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells. Endocrinology 143: 3376-3384.
43. Swerdlow AJ, Jones ME, (2005) Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst 97: 375-384.
44. Moorthy B, Sriram P, Randerath E, Randerath K, (1997) Effects of cytochrome P450 inducers on tamoxifen genotoxicity in female mice in vivo. Biochem Pharmacol 53: 663-669.
45. Shibutani S, Ravindernath A, Suzuki N, Terashima I, Sugarman SM, et al. (2000) Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 21: 1461-1467.
46. Lee H, Jiang F, Wang Q, Nicosia SV, Yang J, et al. (2000) MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. Mol Endocrinol 14: 1882-1896.
47. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, et al. (2006) The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 20: 631-646.
48. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, et al. (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66: 1630-1639.
49. Chu I, Blackwell K, Chen S, Slingerland J, (2005) The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 65: 18-25.
50. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, et al. (2005) Endometrial cancer. Lancet 366: 491-505.
51. Acconcia F, Barnes CJ, Kumar R, (2006) Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells. Endocrinology 147: 1203-1212.